Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Raxtozinameran is a Pfizer mRNA vaccine used to prevent COVID-19 caused by SARS-CoV-2. Raxtozinameran is also known as Pfizer-BioNTech COVID-19 Vaccine and Comirnaty.
- Mechanism
- Curator reviewed · 5 references
The nucleoside-modified messenger RNA in raxtozinameran encodes for the viral spike (S) protein of SARS-CoV-2 Omicron variant lineage XBB.1.5. It recognizes and binds to the host cell receptor ACE-2, allowing the virus to attach to and enter host cells. The mRNA is formulated in lipid nanoparticles, which enable delivery of the RNA into host cells to allow expression of the SARS-CoV-2 S antigen. The mRNA codes for membrane-anchored, full-length S with two point mutations within the central helix: These mutations locks S in an antigenically preferred prefusion conformation. The vaccine elicits both neutralizing antibody and cellular immune responses to the spike (S) antigen, which may contribute to protection against COVID-19 disease.
- Primary indication
- Raxtozinameran is indicated for the active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.Curator reviewed · 1 structured indication
- First approval
- Canada, 2023 · United States, 2023
- Also known as
- BNT162b2 Omicron (XBB.1.5) · messenger RNA (mRNA), 5'-capped, encoding a full-length, codon-optimised pre-fusion stabilised conformation variant (K982P and V983P) of the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) spike (S) glycoprotein (Omicron sub-lineage XBB.1.5; · Pfizer-BioNTech COVID-19 Vaccine 2023-2024 · RBP-020.2 4 (XBB.1.5 variant) · RNA (recombinant 5′-[1,2-[(3′-O-methyl)m7G-(5′→5′)-ppp-Am]]-capped all uridine→N1-methylpseudouridine-substituted severe acute respiratory syndrome coronavirus 2 spike glycoprotein secretory signal peptide plus codon-optimized pre-fusion spik
Resolves to
What you can answer from here — as of October 16, 2025
Which drugs share a target with Raxtozinameran, and which of those have an active Phase 3 trial?